Ceapin-A7: Selective ER Stress Blocker for ATF6α Pathway Inh
2026-07-08
Ceapin-A7 is a selective ER stress blocker that specifically inhibits ATF6α pathway activation, enabling precise modulation of the unfolded protein response. APExBIO supplies Ceapin-A7 (SKU BA3709) for research into ER stress signaling and related disease models.
Demethyleneberberine: Protocols and Advantages in Disease Mo
2026-07-07
Demethyleneberberine (DMB) stands out as a multi-targeted, natural isoquinoline alkaloid with robust anti-inflammatory, neuroprotective, and anti-cancer potential. This article unpacks optimized workflows, troubleshooting guidance, and translational insights for leveraging DMB in cell culture and animal models, while highlighting actionable innovations from recent Huntington’s disease research.
Suhuang Capsule Inhibits NLRP3 Inflammasome via ER Stress Mo
2026-07-07
This study reveals that Suhuang antitussive capsule protects against pulmonary dysfunction in cough variant asthma by inhibiting NLRP3 inflammasome activation through suppression of endoplasmic reticulum (ER) stress. The findings highlight the mechanistic link between ER stress, mitochondrial dynamics, and inflammasome-mediated inflammation, offering new insights for therapeutic strategies.
U-73122: Advancing PLC Inhibition for Translational Oncology
2026-07-06
Explore how U-73122, a potent phospholipase C inhibitor from APExBIO, empowers translational researchers to dissect PLC-β2-mediated pathways in cancer and inflammation. This article connects mechanistic insight into calcium flux and chemotaxis modulation with practical, evidence-based strategies—building on recent findings in breast cancer invasiveness and positioning U-73122 as a crucial tool for next-generation biomedical investigations.
Alfuzosin Hydrochloride: Innovations in Gastroretentive Deli
2026-07-06
Explore the advanced pharmaceutical science behind Alfuzosin HCl, a selective α1 adrenoceptor antagonist. This article reveals new insights into gastroretentive systems for BPH research, highlighting the compound's unique assay and formulation considerations.
Lovastatin: Applied Protocols for HMG-CoA Reductase Inhibiti
2026-07-05
Lovastatin’s robust inhibition of HMG-CoA reductase empowers researchers to dissect cholesterol biosynthesis, cell proliferation, and apoptosis in vitro and in vivo. This guide delivers actionable protocols, troubleshooting insights, and workflow enhancements to maximize the impact of Lovastatin in advanced metabolic and cancer research.
Belinostat (PXD101) in Cancer Research: Mechanistic Insights
2026-07-04
Explore how Belinostat (PXD101), a potent pan-HDAC inhibitor, enables advanced epigenetic cancer research. This article delivers mechanistic depth and practical assay strategies, building on recent innovations in in vitro drug response evaluation.
PDHA1 Succinylation Drives α-KG–Mediated Immune Evasion in C
2026-07-03
The referenced study uncovers how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma drives metabolic reprogramming, leading to α-ketoglutaric acid accumulation and suppression of macrophage antigen presentation. These findings clarify a critical metabolic-immune axis underlying chemotherapy resistance and highlight the therapeutic promise of targeting PDHA1 succinylation.
Triiodothyronine (T3): Precision Control of Thermogenic Assa
2026-07-03
Explore how Triiodothyronine (T3) enables next-generation control of thermogenic and adipocyte differentiation assays. This article unveils the molecular interplay between T3, thyroid hormone receptor activation, and SEMA3E-driven thermogenesis, offering practical, evidence-backed workflow guidance.
Triptolide (PG490): Precision Inhibition in Cancer Research
2026-07-02
Triptolide (PG490) from APExBIO delivers nanomolar-range, evidence-backed precision for inhibiting transcriptional and proteolytic pathways in cancer and immunology research. This guide distills experimental strategies, protocol optimizations, and troubleshooting tips—anchored by the latest pluripotency network findings—for robust, reproducible results.
AZ505 SMYD2 Inhibitor: Transforming Epigenetic & Fibrosis Re
2026-07-02
AZ505, a potent and selective SMYD2 inhibitor from APExBIO, empowers precise dissection of epigenetic mechanisms in cancer and fibrosis models. Its substrate-competitive inhibition profile and nanomolar potency enable reproducible, high-specificity results in both cellular and in vivo assays.
Nebivolol Hydrochloride: Precision β1-Adrenoceptor Antagonis
2026-07-01
Nebivolol hydrochloride is a highly selective β1-adrenoceptor antagonist with nanomolar potency. It provides a validated tool for dissecting β1-adrenergic receptor signaling in cardiovascular pharmacology research. Recent evidence confirms its lack of mTOR pathway inhibition, clarifying its mechanistic boundaries for translational studies.
AI-10-49 and the N-MYC/eIF4G1 Axis: Redefining AML Research
2026-07-01
AI-10-49, a selective CBFβ-SMMHC inhibitor, empowers translational researchers to dissect and therapeutically target oncogenic fusion protein-driven survival pathways in acute myeloid leukemia (AML), particularly the N-MYC/eIF4G1 axis in inv(16) AML. This article integrates mechanistic insights, experimental workflow strategies, and forward-looking perspectives, offering a roadmap for next-generation leukemia research and highlighting how APExBIO’s AI-10-49 enables restoration of RUNX1 activity and disruption of leukemic proliferation.
Uridine, Trisodium Salt: Optimizing RNA-Only Transgene Engin
2026-06-30
Explore how Uridine, Trisodium Salt enables next-generation, RNA-only transgene insertion and vascular studies. This article delivers a deeper mechanistic analysis and practical assay design guidance for researchers leveraging nucleoside analogs.
TMEM16F in Kupffer Cells Restricts Liver Injury from Listeri
2026-06-30
This study uncovers the essential role of TMEM16F in Kupffer cells for protecting the liver from Listeria monocytogenes infection. By demonstrating that TMEM16F-mediated membrane repair in these macrophages prevents cell death, inflammation, and metabolic disruption, the work advances understanding of host defense mechanisms and offers new directions for dissecting necrotic cell death pathways.
466 records 13/32 page Previous Next First page 上5页 1112131415 下5页 Last page